Establishment and Evaluation of the DSS-Induced Colitis Model

Dextran Sodium Sulfate (DSS) induced colitis is the most widely utilized preclinical model for studying inflammatory bowel disease (IBD) due to its simplicity and high reproducibility. This technical article provides a comprehensive guide on the DSS-induced colitis model experimental protocol, covering mechanisms, sample collection, and key evaluation parameters for drug screening and pathogenesis research.

Technical Overview

The DSS-induced colitis model is a cornerstone in gastroenterological research, primarily used to mimic human ulcerative colitis. DSS is a sulfated polysaccharide that, when administered in drinking water, causes toxicity to colonic epithelial cells, leading to the disruption of the mucosal barrier. This disruption allows for the translocation of luminal bacteria into the submucosa, triggering a robust inflammatory response characterized by the infiltration of neutrophils and macrophages. The model is highly valued for its rapid induction of acute inflammation, typically occurring within 5 to 7 days, and its ability to simulate key pathological features such as mucosal ulceration, crypt loss, and diarrhea.

Testing Samples

Colon Tissue

The colon is the primary target organ in this model. Upon termination of the experiment, the entire colon (from the ileocecal junction to the anus) is excised. The colon length and weight are recorded as macroscopic indicators of inflammation severity. The tissue is then divided for various downstream analyses, including histology and molecular biology.

Blood and Serum

Blood samples are collected via cardiac puncture or retro-orbital bleeding. Serum is isolated to quantify systemic inflammatory markers and cytokine levels. This helps in evaluating the systemic immune response triggered by local colonic inflammation.

Fecal Samples

Feces are collected during the disease induction phase to monitor disease progression through scoring systems and to analyze alterations in the gut microbiota composition using 16S rRNA sequencing.

Testing Items

The evaluation of the DSS-induced colitis model involves a multi-parametric approach to ensure comprehensive data collection.

• Disease Activity Index (DAI): A composite score based on weight loss, stool consistency, and the presence of fecal blood.
• Colon Length and Spleen Weight: Shortening of the colon and splenomegaly are reliable macroscopic markers of inflammation.
• Histopathological Scoring: Microscopic evaluation of mucosal damage, crypt architecture, and inflammatory cell infiltration using Hematoxylin and Eosin (H&E) staining.
• Inflammatory Cytokines: Quantification of TNF-alpha, IL-1beta, IL-6, and IL-17 using ELISA or qPCR.
• Myeloperoxidase (MPO) Activity: A specific marker for neutrophil infiltration in the colon tissue.

Testing Methods

Model Induction Protocol

The standard method involves dissolving DSS powder in sterile drinking water at concentrations ranging from 1.5% to 5% (w/v), depending on the DSS molecular weight (commonly 36-50 kDa) and the animal strain. Mice are allowed free access to the DSS water for a specific cycle, typically 5 to 7 days for acute colitis. For chronic colitis models, cycles of DSS administration are alternated with periods of normal water consumption to allow for recovery and fibrosis development.

Histological Processing

Colonic tissue samples are fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned. The sections are stained with H&E for general morphology. Periodic Acid-Schiff (PAS) staining may be used to visualize goblet cell depletion, a hallmark of colitis.

Molecular Analysis

Tissue homogenates are prepared for protein extraction to perform Western blotting or ELISA. For gene expression analysis, total RNA is extracted using Trizol reagent, reverse transcribed into cDNA, and analyzed via quantitative real-time PCR (qPCR) for inflammatory gene markers.

Applications

The DSS-induced colitis model is extensively used in both academic and pharmaceutical research settings.

• Drug Efficacy Screening: Testing the therapeutic potential of small molecules, biologics, and natural products for IBD treatment.
• Mechanism of Action Studies: Investigating the specific pathways involved in intestinal inflammation and mucosal healing.
• Microbiome Research: Analyzing the reciprocal relationship between gut dysbiosis and inflammatory bowel disease.
• Preclinical Safety Assessment: Evaluating the gastrointestinal side effects of non-IBD drugs.

FAQ

What is the most critical factor influencing model consistency?

The molecular weight of DSS is the most critical variable. Lower molecular weight DSS (e.g., 5 kDa) may not induce significant inflammation, while higher molecular weights (e.g., 40-50 kDa) are standard. Batch-to-batch variability of DSS is also a known issue, requiring pre-testing for every new lot.

Why is monitoring body weight important?

Weight loss is the earliest and most sensitive indicator of disease onset in the DSS model. A weight loss of greater than 20% is often established as a humane endpoint in animal ethics protocols.

Can this model represent Crohn's Disease?

The DSS model primarily mimics ulcerative colitis due to the superficial mucosal damage and restriction to the colon. To model Crohn's disease, which involves transmural inflammation, researchers typically utilize the TNBS (Trinitrobenzene sulfonic acid) model or transgenic models such as SAMP1/Yit mice.